title: The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension.
abstract: The effectiveness of dorzolamide 2%, a topical carbonic anhydrase inhibitor, administered three times daily (TID) concomitantly with timolol 0.5% given twice daily (BID) was evaluated in one arm of a large, 1-year, multicenter efficacy and safety trial. That study compared dorzolamide 2% TID with betaxolol 0.5% BID and timolol 0.5% BID as monotherapy in patients with open-angle glaucoma or ocular hypertension. Ninety-seven patients with uncontrolled intraocular pressure (IOP) (ie, greater than 21 mm Hg) or with a reduction in IOP of less than 15% from baseline during monotherapy with dorzolamide required 0.5% timolol BID as adjunctive therapy; 95 patients were evaluated for efficacy. IOP was measured 1 week after starting adjunctive therapy and at all subsequent study visits. Data were evaluated as change in IOP from original baseline and change in IOP from end of monotherapy treatment. A clinically meaningful additive effect on IOP was observed at all time points. After 1 week of adjunctive therapy, the mean percent reduction from baseline in peak and afternoon trough IOPs was 34% and 28%, respectively. These results demonstrate that dorzolamide and timolol have an additive effect in lowering IOP. This combination was generally well tolerated by the patients in this study.
authors.affiliation: Merck & Co., Inc., West Point, Pennsylvania, USA.
authors.forename: D
authors.initials: D
authors.lastname: Hartenbaum
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*; D014794:Visual Fields
chemical_list: D000319:Adrenergic beta-Antagonists; D002257:Carbonic Anhydrase Inhibitors; D013449:Sulfonamides; D013876:Thiophenes; D013999:Timolol; C062765:dorzolamide